Gonadorelin-Related Trial NCT05161195 Now Active, Not Recruiting

A clinical trial update dated September 18, 2026 reports the status of a Phase 4 study titled "Roll-over Study to Allow Continued Access to Ribociclib," registered as NCT05161195. The trial is listed as active, not recruiting, meaning enrollment is currently closed but participants already involved continue in the study. This is a Phase 4 trial, which typically monitors approved treatments in ongoing use. The registry entry does not report any results, outcomes, or new findings at this time. No efficacy or safety conclusions are stated in this update. The record does not specify additional details about study arms or endpoints beyond its status and phase. Gonadorelin is an approved compound, and its association with this trial listing is noted here as reported. Readers should note that this update reflects only the administrative status of the trial as recorded in the registry entry. No dosing information, treatment recommendations, or interpretations of therapeutic value are included in this brief. For more background on gonadorelin, including its approved uses and general profile, readers can consult the compound overview.